In conclusion, our data showed that plasma levels of TIMP-1 in COVID-19 patients correlated with the severity of the disease as well as with inflammatory markers and the chest CT score, suggesting that TIMP-1 could serve as a non-invasive biomarker for prognosis and lung fibrosis in COVID-19. This evidence concerns the gene TIMP1 and pulmonary fibrosis.